Literature DB >> 5558887

Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU.

R C Young, V T DeVita, A A Serpick, G P Canellos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5558887     DOI： 10.1056/NEJM197108262850902

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

Review 1.  [Diagnostic and therapeutic procedures in Hodgkin's disease].

Authors:  D Huhn; C Steidle
Journal:  Blut       Date:  1973-08

Review 2.  Antineoplastic and immunosuppressive drugs. II. Therapeutic uses.

Authors:  M D Cridland
Journal:  Drugs       Date:  1972       Impact factor: 9.546

Review 3.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

4.  H2-antagonists and carmustine.

Authors:  R T Dorr; M J Soble
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

5.  Bleomycin in the reticuloses.

Authors: 
Journal:  Br Med J       Date:  1972-01-29

6.  Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.

Authors:  S R Wedge; J K Porteus; B L May; E S Newlands
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

7.  3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.

Authors:  S R Wedge; J K Porteous; E S Newlands
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

Review 8.  Achievements of cancer chemotherapy.

Authors:  J S Tobias; J M Whitehouse
Journal:  J R Coll Physicians Lond       Date:  1976-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.